UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Jun

    27

    Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis

    Read More

    Jun

    27

    UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

    Read More

    Jun

    14

    Recognizing Ethical Leadership at UCB

    Read More

    Jun

    02

    Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome

    Read More

    Jun

    01

    Myasthenia Gravis Awareness Month is the Time to Understand More About the Lived Experiences of the Community

    Read More

    © 2026 UCB, Inc., Smyrna, GA 30080. All rights reserved.
    US-DA-2500920